- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Treating Hyperglycemia Early Could Reduce CV Risks, Study Shows
Published in Diabetes Care, the study found that earlier detection, and importantly, initiating treatment early, can reduce cardiovascular risks.
A study published in Diabetes Care found that earlier detection, and importantly, initiating treatment early, can reduce cardiovascular risks.
The authors retrospectively analysed patient data from a large European study of people 40 to 69 years old without known diabetes who were screened and treated for the condition. While in the original study, some patients with hyperglycemia were treated intensively while others were given standard treatment, no difference in cardiovascular outcomes or death was documented 5 years later. To predict outcomes in thes same population if screening had been delayed by another 3 to 6 years, the researchers of the current study used a simulation model.
The results: a 3 year delay could have resulted in 11% of people experiencing a heart problem within 5 years, compared to about 8% when screening wasn't delayed. If screening was delayed by 6 years, they estimated that about 13% of participants would experience a heart problem over the 5 years.
Complete article on Medscape: http://wb.md/1HPL36j
Pulmonary Hypertension Subtypes Show Distinct PA Flow Hemodynamics
March 21st 2025Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) remodeling in pulmonary arterial hypertension and other types of pulmonary hypertension.
Read More
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
